Table 1.

Toxicity evaluation from multiple courses of US-delivered chemotherapy.

Nontumor-bearing micei.c. glioma PDX modela
TreatmentMortalitySigns of CNS PathologyMortalitySigns of CNS pathologyTotal survival (%)
Ultrasound only0/82/4 Small focal white matter vacuolation (WMV), Hemosiderin-laden macrophages (HLM)0/1927/27 (100%)
Ultrasound + Cremophor EL PTX (12 mg/kg)4/73/4 severe necrosis, hemorrhage, Diffuse axonal injury (DAI), hippocampal damage3/7 (42%)
Ultrasound + Cremophor EL (5% in Saline)3/81/3 DAI 2/3 small focal WMV5/8 (62.5%)
Ultrasound + Abraxane (12 mg/kg)1/63/4 Focal WMV0/2025/26 (96%)
Ultrasound + Abraxane (24 mg/kg)0/51/3 HLM5/211/3 cytotoxic edema 1/3 DAI 1/3 focal WMV21/26 (81%)
Ultrasound + Abraxaneb (24 mg/kg)0/1010/10 (100%)
  • aIn intracranial glioma PDX model mice, deaths were considered due to treatment if the day of death was considered significantly different from control untreated tumor-bearing mice (P < 0.0005).

  • bMice received treatment twice a week (MTh) × 4 weeks instead of 8 courses of treatment over 3 weeks.